Aker Biomarine ASA
OSE:AKBM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.1095
59.5148
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Aker Biomarine ASA
Total Liabilities & Equity
Aker Biomarine ASA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aker Biomarine ASA
OSE:AKBM
|
Total Liabilities & Equity
$827.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Orkla ASA
OSE:ORK
|
Total Liabilities & Equity
kr89.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Leroy Seafood Group ASA
OSE:LSG
|
Total Liabilities & Equity
kr39.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
12%
|
|
|
SalMar ASA
OSE:SALM
|
Total Liabilities & Equity
kr52.9B
|
CAGR 3-Years
30%
|
CAGR 5-Years
25%
|
CAGR 10-Years
19%
|
|
|
Austevoll Seafood ASA
OSE:AUSS
|
Total Liabilities & Equity
kr53.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Mowi ASA
OSE:MOWI
|
Total Liabilities & Equity
€8.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
Aker Biomarine ASA
Glance View
Aker BioMarine AS operates as a biotech innovator and Antarctic krill-harvesting company which develops krill-based ingredients for nutraceutical, aquaculture, and animal feed applications. The company is headquartered in Lysaker, Akershus. The company went IPO on 2020-07-06. The company consists of two business segments: Ingredients and Brands. Under The Ingredients segment, the Company develops krillbased ingredients for human applications in the nutraceutical and dietary supplement space, and animal feed applications for aquaculture and pet food. Under The Brands segment, the Company has two companies: Lang Pharma Nutrition and Epion Brands. Lang Pharma Nutrition is a full service, mass market private label and corporate brand manufacturer within supplements. Epion Brands has its own consumer brand in the US market, Kori, being on the shelves of retailers. Aker BioMarine’s focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste.
See Also
What is Aker Biomarine ASA's Total Liabilities & Equity?
Total Liabilities & Equity
827.1m
USD
Based on the financial report for Dec 31, 2023, Aker Biomarine ASA's Total Liabilities & Equity amounts to 827.1m USD.
What is Aker Biomarine ASA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
14%
Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for Aker Biomarine ASA have been 6% over the past three years , 14% over the past five years .
You don't have any saved screeners yet
